IRVINE, Calif., Feb. 19, 2014 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, reported today that total revenues for the fourth quarter and twelve months ended December 31, 2013 increased to $1.75 million and $6.37 million, respectively, up 18 percent and 19 percent from the comparable periods in 2012, respectively. Revenues from the Company’s core prenatal microarray testing markets grew by 57 percent in the fourth quarter of 2013 over the corresponding period in 2012, and by 112 percent year-over-year. Sequentially, prenatal microarray testing revenues grew by 22% from the third quarter of 2013 to the fourth quarter. Prenatal microarray volumes grew by 74 percent and 126 percent in the fourth quarter and twelve months ended December 31, 2013, respectively, from the comparable periods in 2012. Billable prenatal microarray tests were 674 and 2,222 for the three and twelve months ended December 31, 2013, both of which represent record prenatal microarray volumes for the Company.
Help employers find you! Check out all the jobs and post your resume.
